PMID- 27073682
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220321
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 4
IP  - 4
DP  - 2016 Apr
TI  - Maintenance monotherapy with Gemcitabine following cisplatin-based primary 
      combination chemotherapy in surgically treated advanced urothelial carcinoma: A 
      matched-pair single institution analysis.
PG  - 636-642
AB  - The role of maintenance therapy with Gemcitabine (GEM) following cisplatin-based 
      combination chemotherapy (CBCC) in patients with surgically treated advanced 
      urothelial carcinoma (UC) remains to be fully elucidated. In the present case 
      control study, a retrospective analysis was performed to evaluate the role of GEM 
      monotherapy following surgical intervention for advanced UC. Between 1999 and 
      2013, 38 patients were identified with surgically treated advanced UC after 
      having completed CBCC, who were additionally treated quarterly with two 
      consecutive GEM (1,250 mg/m(2)) infusions as maintenance therapy. This collective 
      was matched by propensity score matching to a control collective (n=38) that 
      received primary CBCC alone, and the overall survival (OS), cancer-specific 
      survival (CSS) and progression-free survival (PFS) rates were determined for the 
      two collectives using Kaplan-Meier estimates and the log-rank test. Regression 
      analysis was performed using the Cox proportional hazards model. The median 
      follow-up time was 37 months (interquartile range: 9-148). Interestingly, 
      patients treated with GEM following primary chemotherapy had a significantly 
      improved outcome with respect to the 5-year OS (46.2 vs. 26.4%, P=0.0314) and 
      5-year CSS (61.3 vs. 33.4%, P=0.0386) rates. Notably, the 5-year PFS rate did not 
      differ between the two groups (10.3 vs. 16.1%, P=0.134). It is proposed that 
      additional GEM maintenance monotherapy is able to improve survival rates 
      following primary CBCC in surgically treated patients with advanced UC, 
      suggesting a possible treatment option for patients with, e.g., unclear disease 
      status, or those who would require an active maintenance therapy in the future. 
      Prospective studies should further determine the impact of GEM monotherapy with 
      respect to PFS rates in groups comprising larger numbers of patients.
FAU - Kalogirou, Charis
AU  - Kalogirou C
AD  - Department of Urology and Paediatric Urology, Julius Maximilians University 
      Medical Center of Wurzburg, D-97080 Wurzburg, Germany.
FAU - Svistunov, Andrey
AU  - Svistunov A
AD  - Department of Urology and Paediatric Urology, Julius Maximilians University 
      Medical Center of Wurzburg, D-97080 Wurzburg, Germany.
FAU - Krebs, Markus
AU  - Krebs M
AD  - Department of Urology and Paediatric Urology, Julius Maximilians University 
      Medical Center of Wurzburg, D-97080 Wurzburg, Germany.
FAU - Lausenmeyer, Eva Maria
AU  - Lausenmeyer EM
AD  - Department of Urology, University of Regensburg, D-93053 Regensburg, Germany.
FAU - Vergho, Daniel
AU  - Vergho D
AD  - Department of Urology and Paediatric Urology, Julius Maximilians University 
      Medical Center of Wurzburg, D-97080 Wurzburg, Germany.
FAU - Riedmiller, Hubertus
AU  - Riedmiller H
AD  - Department of Urology and Paediatric Urology, Julius Maximilians University 
      Medical Center of Wurzburg, D-97080 Wurzburg, Germany.
FAU - Kocot, Arkadius
AU  - Kocot A
AD  - Department of Urology and Paediatric Urology, Julius Maximilians University 
      Medical Center of Wurzburg, D-97080 Wurzburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20160128
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC4812178
OTO - NOTNLM
OT  - Gemcitabine
OT  - bladder cancer
OT  - monotherapy
OT  - urothelial carcinoma
EDAT- 2016/04/14 06:00
MHDA- 2016/04/14 06:01
PMCR- 2016/01/28
CRDT- 2016/04/14 06:00
PHST- 2015/10/23 00:00 [received]
PHST- 2016/01/13 00:00 [accepted]
PHST- 2016/04/14 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/04/14 06:01 [medline]
PHST- 2016/01/28 00:00 [pmc-release]
AID - MCO-0-0-749 [pii]
AID - 10.3892/mco.2016.749 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2016 Apr;4(4):636-642. doi: 10.3892/mco.2016.749. Epub 2016 Jan 
      28.